Russia has announced a major breakthrough with the introduction of an “anti-aging vaccine.” This gene therapy aims to slow cellular decay by blocking the RAGE receptor, which is a major trigger for age-related changes in the human body.
Researchers have successfully conducted experimental procedures specifically designed to inhibit this receptor and stop the biological processes that induce aging.
The project is being developed by the Institute of Aging Biology and Medicine as part of Russia’s significant effort to expand domestic biotechnology research.
This initiative directly addresses the economic and social challenges posed by Russia’s declining and aging population.
To this end, Russian authorities have framed longevity research as a public health priority and a matter of national security. The Kremlin continues to promote scientific programs aimed at extending healthy life expectancy and ensuring the nation’s long-term vitality.
“The RAGE gene is a receptor whose activation initiates the aging of the cell. Conversely, blocking this gene can prolong its youthfulness,” Sekirinsky said at a healthy longevity conference in the Volga city of Saransk, according to the state-run TASS news agency.
Deputy Prime Minister Tatyana Golikova said Russia plans to introduce an anti-aging drug between 2028 and 2030. Under the national project “New Technologies for Health Protection” launched in 2025; The program’s budget exceeds 2 trillion rubles ($26.4 billion).
According to sources close to the Kremlin, the project was led by Mikhail Kovalchuk, who has been described as having a passion for eternal life and “the genome of the Russian person”.
Furthermore, the recent announcement reflects the intensifying global scientific competition, with nations investing heavily in gene editing, regenerative medicine and technologies aimed at expanding health. If this research proves successful, Russia could emerge as a significant player in the global anti-aging medical field.
